Evidence map›Paper›PMID 31671695›Full record

ArticleCells2019

The Oncogene AF1Q is Associated with WNT and STAT Signaling and Offers a Novel Independent Prognostic Marker in Patients with Resectable Esophageal Cancer.

Elisabeth S Gruber, Georg Oberhuber, Peter Birner, Michaela Schlederer, Michael Kenn, Wolfgang Schreiner, Gerd Jomrich, Sebastian F Schoppmann, Michael Gnant, William Tse and 1 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 3 countries.

Elisabeth S GruberDivision of General Surgery, Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria. elisabeth.s.gruber@meduniwien.ac.at.
Georg OberhuberInstitute of Pathology, Department of Experimental and Translational Pathology, Medical University of Vienna, 1090 Vienna, Austria. georg.oberhuber@patho.at.
Peter BirnerInstitute of Pathology, Department of Experimental and Translational Pathology, Medical University of Vienna, 1090 Vienna, Austria. peter.birner@meduniwien.ac.at.
Michaela SchledererInstitute of Pathology, Department of Experimental and Translational Pathology, Medical University of Vienna, 1090 Vienna, Austria. michaela.schlederer@meduniwien.ac.at.
Michael KennSection of Biosimulation and Bioinformatics, Center for Medical Statistics, Informatics and Intelligent Systems (CeMSIIS), Medical University of Vienna, 1090 Vienna, Austria. michael.kenn@meduniwien.ac.at.
Wolfgang SchreinerSection of Biosimulation and Bioinformatics, Center for Medical Statistics, Informatics and Intelligent Systems (CeMSIIS), Medical University of Vienna, 1090 Vienna, Austria. wolfgang.schreiner@meduniwien.ac.at.
Gerd JomrichDivision of General Surgery, Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria. michael.gnant@meduniwien.ac.at.
Sebastian F SchoppmannDivision of General Surgery, Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria. sebastian.schoppmann@meduniwien.ac.at.
Michael GnantDivision of General Surgery, Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria. michael.gnant@meduniwien.ac.at.
William TseJames Graham Brown Cancer Center, University of Louisville School of Medicine, Louisville, KY 40202, USA. william.tse@louisvolle.edu.
Lukas KennerInstitute of Pathology, Department of Experimental and Translational Pathology, Medical University of Vienna, 1090 Vienna, Austria. lukas.kenner@meduniwien.ac.at.
Comprehensive Cancer Center Vienna · ATMedical University of Vienna · ATStatistics Austria · ATGeorg Fischer (Switzerland) · CHUniversity of Louisville · USUniversity of Veterinary Medicine Vienna · AT

Funding

Austrian Science Fund FWF P 26011
6 · The paper itself

Abstract

AF1q impairs survival in hematologic and solid malignancies. AF1q expression is associated with tumor progression, migration, and chemoresistance, and acts as a transcriptional co-activator in WNT and STAT signaling. This study evaluates the role of AF1q in patients with resectable esophageal cancer (EC). A total of 278 patients operated on for esophageal cancer were retrospectively included, and the expression of AF1q, CD44, and pYSTAT3 was analyzed following immunostaining. Quantified data were processed to correlational and survival analysis. In EC patients, an elevated expression of AF1q was associated with CD44 (

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorEsophageal NeoplasmsEsophagectomyFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansHyaluronan ReceptorsMaleMiddle AgedNeoplasm ProteinsNeoplasm Recurrence, LocalOncogenesBiomarkers, TumorCD44 protein, humanHyaluronan ReceptorsMLLT11 protein, humanNeoplasm ProteinsProto-Oncogene ProteinsSTAT1 protein, humanSTAT1 Transcription FactorWnt1 ProteinWNT1 protein, humanAF1Qesophageal cancerMLLT11prognosisSTATWNT

Identifiers

PMID31671695
PMCPMC6912824
OpenAlexW2982340739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.